<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574587</url>
  </required_header>
  <id_info>
    <org_study_id>07-10-374</org_study_id>
    <secondary_id>NYCC1</secondary_id>
    <secondary_id>NCI-2013-01216</secondary_id>
    <nct_id>NCT00574587</nct_id>
  </id_info>
  <brief_title>Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy</brief_title>
  <official_title>Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vorinostat is a histone deacetylase (HDAC) inhibitor which is approved by the U.S. Food and&#xD;
      Drug Administration for the treatment of a rare type of cancer involving the skin (cutaneous&#xD;
      T cell lymphoma), but not for breast cancer. HDAC inhibitors work by unsilencing tumor&#xD;
      suppressor genes and other genes in the cancer cells that are repressed; when the genes are&#xD;
      turned back on by the drug, it leads to death of the cancer cells. HDAC inhibitors such as&#xD;
      vorinostat have been shown to enhance the effects of chemotherapy and trastuzumab in&#xD;
      experimental systems. The purpose of this trial is to determine the optimal dose of&#xD;
      vorinostat to use in combination with standard chemotherapy alone (or in combination with&#xD;
      plus trastuzumab for HER2-positive disease), and to determine whether vorinostat enhances the&#xD;
      effectiveness of standard chemotherapy (+/- trastuzumab) in patients with locally advanced&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I-II trial in which patients with stage IIB-IIIC breast cancer will receive:&#xD;
&#xD;
        1. Neoadjuvant weekly paclitaxel (80 mg/m2 IV weekly x 12 weeks) plus vorinostat (200 or&#xD;
           300 mg PO BID on days 1-3 each paclitaxel dose) and trastuzumab (4 mg/kg loading dose, 2&#xD;
           mg/kg IV weekly x 12 total doses if HER2 positive, followed by:&#xD;
&#xD;
        2. Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) every 2 weeks x 4 cycles (plus&#xD;
           G-CSF), followed by:&#xD;
&#xD;
        3. Surgery (lumpectomy or mastectomy)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab</measure>
    <time_frame>3 weeks</time_frame>
    <description>Dose limiting toxicity in cycle 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (CR) Rate in Patients With Her2/Neu Positive Locally Advanced Breast Cancer.</measure>
    <time_frame>6 months</time_frame>
    <description>Pathological Complete Response (CR) defined as absence of invasive cancer at surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vorinostat Plus Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks (and trastuzumab if HER2-positive), followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose</description>
    <arm_group_label>Vorinostat Plus Paclitaxel</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 80 mg/m2 weekly for 12 weeks</description>
    <arm_group_label>Vorinostat Plus Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose</description>
    <arm_group_label>Vorinostat Plus Paclitaxel</arm_group_label>
    <other_name>Perception</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks</description>
    <arm_group_label>Vorinostat Plus Paclitaxel</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks</description>
    <arm_group_label>Vorinostat Plus Paclitaxel</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgical excision of tumor from breast</description>
    <arm_group_label>Vorinostat Plus Paclitaxel</arm_group_label>
    <other_name>Mastectomy or lumpectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast associated with&#xD;
             the following stages: IIB, IIIA, IIIB or IIIC.&#xD;
&#xD;
          -  Tumor must be Her2/neu positive&#xD;
&#xD;
          -  No prior chemotherapy, radiation or definitive therapeutic surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  May not be receiving any other investigational agents&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Sparano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <results_first_submitted>March 30, 2020</results_first_submitted>
  <results_first_submitted_qc>August 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Joseph Sparano</investigator_full_name>
    <investigator_title>Professor, Oncology</investigator_title>
  </responsible_party>
  <keyword>Vorinostat</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment: April 2008 - September 2013</recruitment_details>
      <pre_assignment_details>Patients with HER2 positive disease also received trastuzumab.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stratum A (HER2-positive): Dose Level 1</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 200 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="P2">
          <title>Stratum A (HER2-positive): Dose Level 2</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="P3">
          <title>Stratum B: Triple Negative</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="P4">
          <title>Stratum C: ER-Positive, HER2-negative</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stratum A (HER2-positive): Dose Level 1</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 200 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="B2">
          <title>Stratum A (HER2-positive): Dose Level 2</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="B3">
          <title>Stratum B: Triple Negative</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="B4">
          <title>Stratum C: ER-Positive, HER2-Negative</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="30" upper_limit="69"/>
                    <measurement group_id="B2" value="54" lower_limit="30" upper_limit="69"/>
                    <measurement group_id="B3" value="48" lower_limit="41" upper_limit="64"/>
                    <measurement group_id="B4" value="46" lower_limit="30" upper_limit="73"/>
                    <measurement group_id="B5" value="52" lower_limit="30" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab</title>
        <description>Dose limiting toxicity in cycle 1</description>
        <time_frame>3 weeks</time_frame>
        <population>The recommended Phase II Dose of vorinostat was determined in Stratum A and B participants only.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A: VR-Paclitaxel-Trastuzumab</title>
            <description>Stratum A: Vorinostat 200 (Dose Level 1) or 300 mg (Dose level 2) by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks, followed by surgery</description>
          </group>
          <group group_id="O2">
            <title>Stratum B: VR-Paclitaxel-Trastuzumab</title>
            <description>Stratum B: 300 mg by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin 60 mg/m2 -cyclophosphamide 600 mg/m2 every 2 weeks x 8 weeks, followed by surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab</title>
          <description>Dose limiting toxicity in cycle 1</description>
          <population>The recommended Phase II Dose of vorinostat was determined in Stratum A and B participants only.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathological Complete Response (CR) Rate in Patients With Her2/Neu Positive Locally Advanced Breast Cancer.</title>
        <description>Pathological Complete Response (CR) defined as absence of invasive cancer at surgery</description>
        <time_frame>6 months</time_frame>
        <population>Stratum A (HER2-positive): Dose Level 1 and Stratum A (HER2-positive): Dose Level 2 are combined. Data was collected for outcome measures per stratum not per dose level. 2 pts in Stratum A were not evaluable (1 lost to f/u; 1 death); 1 pt was not evaluable in Stratum B (1 death) and 1 pt was not evaluable in C (1 declined surgery)</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum A (HER2-positive)</title>
            <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 200-300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
          </group>
          <group group_id="O2">
            <title>Stratum B: Triple Negative</title>
            <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
          </group>
          <group group_id="O3">
            <title>Stratum C: ER-Positive, HER2-negative</title>
            <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Complete Response (CR) Rate in Patients With Her2/Neu Positive Locally Advanced Breast Cancer.</title>
          <description>Pathological Complete Response (CR) defined as absence of invasive cancer at surgery</description>
          <population>Stratum A (HER2-positive): Dose Level 1 and Stratum A (HER2-positive): Dose Level 2 are combined. Data was collected for outcome measures per stratum not per dose level. 2 pts in Stratum A were not evaluable (1 lost to f/u; 1 death); 1 pt was not evaluable in Stratum B (1 death) and 1 pt was not evaluable in C (1 declined surgery)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.10</p_value>
            <method>Simon's Mimimax 2-stage design</method>
            <param_type>95% Confidence interval</param_type>
            <param_value>54</param_value>
            <ci_percent>20</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34</ci_lower_limit>
            <ci_upper_limit>74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stratum A (HER2-positive): Dose Level 1</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 200 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="E2">
          <title>Stratum A (HER2-positive): Dose Level 2</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="E3">
          <title>Stratum B: Triple Negative</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
        <group group_id="E4">
          <title>Stratum C: ER-Positive, HER2-negative</title>
          <description>Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks and trastuzumab x 12 weeks, followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery&#xD;
Vorinostat: Vorinostat 300 mg PO BID on days 1-3 of each weekly paclitaxel dose&#xD;
Paclitaxel: Paclitaxel 80 mg/m2 weekly for 12 weeks&#xD;
Trastuzumab: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose&#xD;
Doxorubicin: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks&#xD;
Cyclophosphamide: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks&#xD;
Surgery: Surgical excision of tumor from breast</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary emobolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Markenya Mirander</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-862-8840</phone>
      <email>MMIRANDE@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

